期刊
JOURNAL OF INTERNAL MEDICINE
卷 264, 期 4, 页码 295-314出版社
WILEY
DOI: 10.1111/j.1365-2796.2008.02015.x
关键词
coronary heart disease; C-reactive protein
资金
- Medical Research Council [7900510]
- National Heart Lung and Blood Institute of the US NIH [1 R01 HL078578-01]
- Pentraxin Therapeutics Ltd
- British Heart Foundation [FS/05/125]
- Rosetrees Trust
- Wellcome Trust
- BUPA Foundation
- GlaxoSmithKline
- NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL078578] Funding Source: NIH RePORTER
- British Heart Foundation [RG/08/014/24067] Funding Source: researchfish
- Medical Research Council [G7900510] Funding Source: researchfish
- MRC [G7900510] Funding Source: UKRI
Modestly elevated baseline concentrations of C-reactive protein (CRP), the classical acute phase protein, are associated with the long-term risk of coronary heart disease in general populations, whilst the major acute phase response of CRP following myocardial infarction is associated with death and cardiac complications. The pathogenic and clinical significance of these associations is controversial. Here we critically review the evidence and describe large-scale epidemiological studies, novel experiments and possible specific therapies which will rigorously inform the debate. We distinguish between the potential pathogenicity of high acute phase circulating CRP concentrations in individuals with substantial tissue damage and modest but persistent increases in baseline values in generally healthy subjects.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据